Sunday, July 5, 2015

Therapeutic administration of atomoxetine combined with rTMS and occupational therapy for upper limb hemiparesis after stroke: a case series study of three patients

I have no understanding of how this is supposed to work.  Treatment with atomoxetine started 2 weeks before admission to something. What? Admission to the hospital? So you'll have to know your stroke is coming 2 weeks ahead of time. Doesn't anyone have two neurons to rub together and have a coherent thought?  It doesn't say this is in rats or mice so I'm assuming humans
http://link.springer.com/article/10.1007/s13760-015-0503-3
$39.95 / €34.95 / £29.95 *
* Final gross prices may vary according to local VAT.
Get Access

Abstract

Atomoxetine, a selective noradrenaline reuptake inhibitor, has been reported to enhance brain plasticity, but has not yet been used in stroke patients. We reported the feasibility and clinical benefits on motor functional recovery of the combination of repetitive transcranial magnetic stimulation (rTMS) and intensive occupational therapy (OT) in stroke patients. This pilot study was designed to evaluate the additive effects of oral atomoxetine to rTMS/OT in post-stroke hemiparetic patients. The study included three post-stroke patients with upper limb hemiparesis. Treatment with 40 mg/day atomoxetine commenced 2 weeks before admission. After confirming tolerance, the dose was increased to 120 mg/day. Low-frequency rTMS/OT was provided daily for 15 days during continued atomoxetine therapy. Motor function of the affected upper limb was evaluated with the Fugl-Meyer Assessment and Wolf Motor Function test. All patients completed the protocol and showed motor improvement up to 4 weeks after the treatment. No atomoxetine-related side effects were noted. Our protocol of triple therapy of atomoxetine, low-frequency rTMS, and OT is safe and feasible intervention for upper limb hemiparesis after stroke.

No comments:

Post a Comment